Fatigue – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fatigue
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Fatigue – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Fatigue (Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Fatigue (Central Nervous System) pipeline
guide also reviews of key players involved in therapeutic development
for Fatigue and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 2 and 2
respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Fatigue (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fatigue (Central
    Nervous System) by companies and universities/research institutes
    based on information derived from company and industry-specific
    sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Fatigue (Central
    Nervous System) therapeutics and enlists all their major and minor
    projects.
  • The pipeline guide evaluates Fatigue (Central Nervous System)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Fatigue (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Fatigue (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Fatigue (Central Nervous System) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Aoxing Pharmaceutical Company Inc.
  • Chronos Therapeutics Ltd.
  • Helsinn Group
  • K-Pax Pharmaceuticals Inc.
  • Merz Pharma GmbH & Co. KGaA
  • MultiCell Technologies Inc.
  • Resolys Bio Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/z0cbnt

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs